Home MarketAlembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd. Stock Info: As on 2018-02-23 15:47:25

Nse

561.90

-1.80(-0.32%)
Change%
52 Week Range
469.85
15.00
648.00
10.00
Open568.00
Day's Range450.96 - 676.44
Value Traded (in ₹ Cr.) 1.09

Bse

562.90

2.75(0.49%)
Change %
52 Week Range
469.75
20.00
709.30
23.00
Open565.20
Day's Range448.12 - 672.18
Value Traded (in ₹ Cr.) 0.08

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 137,007,545.00 72.68%
Mutual Funds/UTI 6,741,090.00 3.58%
FII 19,713,893.00 10.46%
Employee 0.00 0.00%
Public 20,373,598.00 10.81%
Government 0.00 0.00%
Others 4,095,679.00 2.17%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 3.78
Basic EPS (Rs.) 37.03
Cash EPS 40.85
BVPerShare Excl 81.17
Operating Revenue 158.70
PBDITPerShare 52.38
Dividend 0.00
NPPerShare 37.03
Current Ratio 2.31
Quick Ratio 1.37
PriceToBV 7.40
Earnings 0.06
PBDIT Margin 33.00
PBT Margin 30.52
NP Margin 23.33
Return On Assets 31.89
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,997.26
Total Expenses 2,083.95
EBITDA 987.54
PBT 913.31
PAT 698.14
Net Income 698.14
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,491.44
Total Expenses 997.94
EBITDA 447.78
PBT 492.02
PAT 369.15
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 37.70
Net worth 1,530.28
Investments 37.46
Total Liability 2,189.11
Total debt 0.00
Net block 789.59
Total Assets 2,189.11
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 37.70
Net worth 1,530.28
Investments 37.46
Total Liability 2,189.11
Total debt 0.00
Net block 789.59
Total Assets 2,189.11
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

613.15 607 1.01
603.6668.8

Abbott India Ltd.

5811.3 5754.4 0.99
5470.056125

Ajanta Pharma Ltd.

1374.45 1350.3 1.79
1311.31420

Albert David Ltd.

365.1 365.2 -0.03
357.4395.35

Alembic Ltd.

61.1 60.8 0.49
60.363.45

Alkem Laboratories Ltd.

2181.3 2174.8 0.3
2115.12185

Alpa Laboratories Ltd.

43.75 41.7 4.92
38.346.6
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

50.1 49.35 1.52
48.7554.15

Aarti Drugs Ltd.

608.05 607.05 0.16
602.6680

Aayush Food & Herbs Ltd.

63.6 63.5 0.16
59.166.9

Abbott India Ltd.

5788.4 5746.8 0.72
5445.355950

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 847.53
Cash from investing activities -293.07
Cash from financing activities -274.05
Net change in cash 280.41

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
ICICI Prudential Long Term Equity Fund 1.77%
ICICI Prudential Multicap Fund 1.92%
ICICI Prudential Balanced Fund 0.13%
ICICI Prudential Balanced Advantage Fund 0.13%
SBI Magnum Multiplier Fund 1.33%
Reliance Small Cap Fund 0.42%

ABC India posts Q3 net loss of Rs 2.25 cr

The company reported standalone net loss during the quarter stood at Rs 2.25 crore as compared to net loss of Rs 13.70 crore in the previous year quarter. Net revenue of the company declined moderately by 12.76 per cent at Rs 28.45 crore in October-December quarter of this fiscal as against Rs 32.61 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 33.09 per cent to Rs 29.90 crore from Rs 44.69 crore in year ago period. Other Income grew by 400.00 per cent at Rs 0.05 crore versus (Dec'16 Rs 0.01 crore). Operating Profit slipped by 87.88 per cent to Rs -1.46 crore as against Rs -12.05 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 86.14 per cent in December quarter. Interest declined by 10.78 per cent y-o-y to Rs 0.91 crore, while Taxation decreased by 40.00 per cent at Rs -0.03 crore (Dec'16 Rs -0.05 crore).

23-02-2018 15:37

Zenith Exports L posts Q3 net loss of Rs 1.49 cr

The company reported standalone net loss during the quarter stood at Rs 1.49 crore compared to net profit of Rs 0.51 crore in the previous year quarter. Net revenue of the company declined moderately by 17.19 per cent at Rs 21.87 crore in October-December quarter of this fiscal as against Rs 26.41 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 19.87 per cent to Rs 22.46 crore from Rs 28.03 crore in year ago period. Other Income dipped by 14.81 per cent at Rs 0.23 crore versus (Dec'16 Rs 0.27 crore). Operating Profit slipped by 171.95 per cent to Rs -0.59 crore as against Rs 0.82 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 187.10 per cent in December quarter. Interest grew by 320.00 per cent y-o-y to Rs 0.21 crore, while Taxation increased by 42.86 per cent at Rs 0.30 crore (Dec'16 Rs 0.21 crore).

23-02-2018 15:37

Austin Engg. Co. posts Q3 net loss of Rs 0.70 cr

The company reported standalone net loss during the quarter stood at Rs 0.70 crore as compared to net loss of Rs 0.83 crore in the previous year quarter. Net revenue of the company declined moderately by 9.59 per cent at Rs 16.02 crore in October-December quarter of this fiscal as against Rs 17.72 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 11.67 per cent to Rs 16.42 crore from Rs 18.59 crore in year ago period. Other Income dipped by 92.00 per cent at Rs 0.02 crore versus (Dec'16 Rs 0.25 crore). Operating Profit slipped by 40.00 per cent to Rs -0.39 crore as against Rs -0.65 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 33.60 per cent in December quarter. Interest declined by 33.33 per cent y-o-y to Rs 0.14 crore, while Taxation increased by 25.00 per cent at Rs -0.10 crore (Dec'16 Rs -0.08 crore).

23-02-2018 15:37

Dhoot Industrial Q3 net profit zooms 264.91% at Rs 2.08 cr

The company reported standalone net profit of Rs 2.08 crore for the quarter ended December 31, 2017 as compared to Rs 0.57 crore in the same period last year, registering a year-on-year growth of 264.91 per cent. Net revenue of the company rose moderately by 8.18 per cent at Rs 18.25 crore in October-December quarter of this fiscal as against Rs 16.87 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 5.41 per cent to Rs 16.26 crore from Rs 17.19 crore in year ago period. Other Income grew by 6.71 per cent at Rs 1.75 crore versus (Dec'16 Rs 1.64 crore). Operating Profit surged by 123.60 per cent to Rs 1.99 crore as against Rs 0.89 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 107.62 per cent in December quarter. Interest declined by 38.46 per cent y-o-y to Rs 0.64 crore, while Taxation increased by 18.31 per cent at Rs 0.84 crore (Dec'16 Rs 0.71 crore).

23-02-2018 15:37

ITL Industries Q3 net profit jumps 65.85% at Rs 1.36 cr

The company reported standalone net profit of Rs 1.36 crore for the quarter ended December 31, 2017 as compared to Rs 0.82 crore in the same period last year, registering a year-on-year growth of 65.85 per cent. Net revenue of the company rose moderately by 16.94 per cent at Rs 20.30 crore in October-December quarter of this fiscal as against Rs 17.36 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 17.41 per cent to Rs 18.34 crore from Rs 15.62 crore in year ago period. Other Income grew by 1600.00 per cent at Rs 0.17 crore versus (Dec'16 Rs 0.01 crore). Operating Profit surged by 12.64 per cent to Rs 1.96 crore as against Rs 1.74 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 3.50 per cent in December quarter. Interest declined by 49.02 per cent y-o-y to Rs 0.26 crore, while Taxation increased by 100.00 per cent at Rs 0.28 crore (Dec'16 Rs 0.14 crore).

23-02-2018 15:37

Alembic Pharmaceutic Q3 net profit down 23.79% at Rs 105.04 cr

The company reported standalone net profit of Rs 105.04 crore for the quarter ended December 31, 2017 as compared to Rs 137.83 crore in the same period last year, registering a year-on-year decline of 23.79 per cent. Net revenue of the company declined by 5.36 per cent at Rs 754.91 crore in October-December quarter of this fiscal as against Rs 797.63 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 1.36 per cent to Rs 594.44 crore from Rs 602.63 crore in year ago period. Other Income grew by 52.38 per cent at Rs 0.32 crore versus (Dec'16 Rs 0.21 crore). Operating Profit slipped by 18.07 per cent to Rs 160.47 crore as against Rs 195.86 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 13.44 per cent in December quarter. Interest grew by 128.57 per cent y-o-y to Rs 0.64 crore, while Taxation decreased by 20.68 per cent at Rs 28.73 crore (Dec'16 Rs 36.22 crore).

31-Jan-2018 07:10 PM

Alembic Pharma Q3 net profit rises 52% to Rs 131 cr

Drug firm Alembic Pharmaceuticals today reported a 52.32 per cent jump in its consolidated net profit to Rs 131 crore for the third quarter ended December 31, on account of robust sales. The company had posted a net profit of Rs 86 crore for the corresponding period of the previous fiscal, it said in a BSE filing. Consolidated total income of the company also rose to Rs 840.34 crore for the quarter under consideration, as against Rs 777.38 crore in the same period a year ago. The Indian branded business recovered, showing good growth. The US generics business continues to do well as we pick up market share leading to higher volumes, Alembic Pharmaceuticals MD Pranav Amin said. Aleor, the company's joint venture with Orbicular for dermatology products, filed its first abbreviated new drug application (ANDA), he added.

31-Jan-2018 04:06 PM

Alembic Pharmaceutic - Unaudited Financial Results For The Quarter And Nine Months Period Ended 31St December, 2017.

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.

We enclose herewith the following:

a) Consolidated Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.
b) Standalone Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.
c) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.
d) Press Release.
e) Investor Presentation.

The time of commencement of the Board Meeting was 10:45 a.m. and the time of conclusion was 11:55 a.m.

We request you to kindly take the same on record.

31-Jan-2018 01:45 PM

Alembic Pharmaceutic - Financial Result Updates

Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

31-Jan-2018 12:11 PM

Alembic Pharmaceutic - Outcome of Board Meeting

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.

We enclose herewith the following:

a) Consolidated Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.
b) Standalone Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.
c) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.
d) Press Release.
e) Investor Presentation.

The time of commencement of the Board Meeting was 10:45 a.m. and the time of conclusion was 11:55 a.m.

We request you to kindly take the same on record.

31-Jan-2018 12:09 PM

Alembic Pharmaceutic - Unaudited Financial Results For The Quarter And Nine Months Period Ended 31St December, 2017.

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.

We enclose herewith the following:

a) Consolidated Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.
b) Standalone Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.
c) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.
d) Press Release.
e) Investor Presentation.

The time of commencement of the Board Meeting was 10:45 a.m. and the time of conclusion was 11:55 a.m.

We request you to kindly take the same on record.

31-Jan-2018 01:45 PM

Alembic Pharmaceutic - Outcome of Board Meeting

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.

We enclose herewith the following:

a) Consolidated Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.
b) Standalone Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2017.
c) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.
d) Press Release.
e) Investor Presentation.

The time of commencement of the Board Meeting was 10:45 a.m. and the time of conclusion was 11:55 a.m.

We request you to kindly take the same on record.

31-Jan-2018 12:09 PM

Alembic Pharmaceutic - Analyst / Investor Meet - Intimation

The exchange is hereby informed that the Company will hold Post Results Conference Call on 31st January, 2018 as per the enclosed details.

Kindly take the same on record.

22-Jan-2018 03:19 PM

Corporate Details

About Management

2011 Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010. The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals Limited and the Registrar of Companies, Gujarat has approved the change of name and issued a fresh certificate of incorporation consequent upon change of name on 12th March, 2011. 2012 Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr). Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. 2013 -Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. 2014 -"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.". 2015 -Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis 2016 - Alembic Pharma inks JV agreement with Orbicular Pharma

Registered Office

Samardung Busty, Namthang,

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.